List view / Grid view
Facing limited viral vector manufacturing capacity, should companies consider further integrating their viral vector supply to address this issue? James Nanista and Josh Hunt of Adaptimmune reflect on the options.
10 February 2016 | By Victoria White
The Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma...
18 December 2015 | By Victoria White
This will be the first study of Adaptimmune’s unpartnered affinity enhanced T-cell therapy targeting MAGE-A10, a highly immunogenic member of the MAGE-A family of cancer testis antigens...